DD154802A5 - Verfahren zur herstellung eines injizierbaren pharmazeutischen praeparates von prolongierter wirkung - Google Patents
Verfahren zur herstellung eines injizierbaren pharmazeutischen praeparates von prolongierter wirkung Download PDFInfo
- Publication number
- DD154802A5 DD154802A5 DD80225492A DD22549280A DD154802A5 DD 154802 A5 DD154802 A5 DD 154802A5 DD 80225492 A DD80225492 A DD 80225492A DD 22549280 A DD22549280 A DD 22549280A DD 154802 A5 DD154802 A5 DD 154802A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- parts
- weight
- volume
- pharmaceutical preparation
- injectable pharmaceutical
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 19
- 230000002035 prolonged effect Effects 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims abstract description 18
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 11
- 239000000654 additive Substances 0.000 claims abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 8
- 230000000996 additive effect Effects 0.000 claims abstract 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 14
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 14
- 229940093471 ethyl oleate Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 229960005404 sulfamethoxazole Drugs 0.000 description 15
- 229960001082 trimethoprim Drugs 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 229940102223 injectable solution Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229940006995 sulfamethoxazole and trimethoprim Drugs 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- MFFXAAMHANMWEY-UHFFFAOYSA-N [Na].C(CCCCCCC)C(C(=O)O)C(C(=O)O)CCCCCCCC Chemical compound [Na].C(CCCCCCC)C(C(=O)O)C(C(=O)O)CCCCCCCC MFFXAAMHANMWEY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 229940099427 potassium bisulfite Drugs 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU79EE2710A HU180740B (en) | 1979-11-27 | 1979-11-27 | Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity |
Publications (1)
Publication Number | Publication Date |
---|---|
DD154802A5 true DD154802A5 (de) | 1982-04-21 |
Family
ID=10995877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DD80225492A DD154802A5 (de) | 1979-11-27 | 1980-11-26 | Verfahren zur herstellung eines injizierbaren pharmazeutischen praeparates von prolongierter wirkung |
Country Status (9)
Country | Link |
---|---|
JP (1) | JPS5687517A (enrdf_load_stackoverflow) |
AT (1) | AT371339B (enrdf_load_stackoverflow) |
BE (1) | BE886310A (enrdf_load_stackoverflow) |
DD (1) | DD154802A5 (enrdf_load_stackoverflow) |
DE (1) | DE3044753A1 (enrdf_load_stackoverflow) |
FR (1) | FR2469924A1 (enrdf_load_stackoverflow) |
GB (1) | GB2066068B (enrdf_load_stackoverflow) |
HU (1) | HU180740B (enrdf_load_stackoverflow) |
IT (1) | IT1149268B (enrdf_load_stackoverflow) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU210693B (en) * | 1991-10-11 | 1995-06-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pharmaceutical compositions for injections without tissue damages, containing sulfamethoxazol and trimetoprime |
CN100376893C (zh) * | 2006-08-18 | 2008-03-26 | 中国水产科学研究院黄海水产研究所 | 同时测定鱼肉中磺胺甲唑、乙酰化磺胺甲唑及甲氧苄啶的液相色谱法 |
CN113952296B (zh) * | 2021-11-15 | 2023-10-13 | 山东新华制药股份有限公司 | 一种复方磺胺甲噁唑注射液的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH544053A (de) * | 1966-05-09 | 1973-11-15 | Hoffmann La Roche | Verfahren zur Herstellung von Sulfonamidderivaten |
US3985876A (en) * | 1973-01-05 | 1976-10-12 | Burroughs Wellcome Co. | Chemotherapeutic solutions containing a sulphur and a salt of a 2,4-diamino-5-benzylpyrimidine |
GB1469521A (en) * | 1973-01-05 | 1977-04-06 | Wellcome Found | Antimicrobial preparations |
DK136934B (da) * | 1976-02-06 | 1977-12-19 | Rosco As | Fremgangsmåde til fremstilling af en klar, stabil, injicerbar opløsning indeholdende et sulfonamid og en potentiator. |
DE2631779A1 (de) * | 1976-07-15 | 1978-01-19 | Basf Ag | Sulfonamid-trimethoprim-loesungen |
-
1979
- 1979-11-27 HU HU79EE2710A patent/HU180740B/hu not_active IP Right Cessation
-
1980
- 1980-11-24 BE BE1/10048A patent/BE886310A/fr not_active IP Right Cessation
- 1980-11-24 FR FR8024891A patent/FR2469924A1/fr active Granted
- 1980-11-26 IT IT26237/80A patent/IT1149268B/it active
- 1980-11-26 GB GB8037932A patent/GB2066068B/en not_active Expired
- 1980-11-26 AT AT0577380A patent/AT371339B/de not_active IP Right Cessation
- 1980-11-26 DD DD80225492A patent/DD154802A5/de not_active IP Right Cessation
- 1980-11-26 JP JP16647880A patent/JPS5687517A/ja active Granted
- 1980-11-27 DE DE19803044753 patent/DE3044753A1/de active Granted
Also Published As
Publication number | Publication date |
---|---|
IT8026227A0 (it) | 1980-11-26 |
BE886310A (fr) | 1981-05-25 |
DE3044753A1 (de) | 1981-06-19 |
GB2066068B (en) | 1983-08-24 |
FR2469924A1 (fr) | 1981-05-29 |
JPS5687517A (en) | 1981-07-16 |
DE3044753C2 (enrdf_load_stackoverflow) | 1990-05-10 |
IT1149268B (it) | 1986-12-03 |
GB2066068A (en) | 1981-07-08 |
ATA577380A (de) | 1982-11-15 |
HU180740B (en) | 1983-04-29 |
JPH0128005B2 (enrdf_load_stackoverflow) | 1989-05-31 |
FR2469924B1 (enrdf_load_stackoverflow) | 1984-06-29 |
AT371339B (de) | 1983-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69104724T2 (de) | Florfenicol enthaltendes arzneimittel. | |
DE1617576C3 (de) | Verfahren zur Herstellung eines Injektionspräparates auf Basis einer wäßrigen Lösung eines Oxytetracyclin-Magnesium-Komplexes | |
DE69329576T2 (de) | Präzipitation einer oder mehrerer aktiver verbindungen in situ | |
DE60121355T2 (de) | Absorptionsverbesserer | |
DE2658237C3 (de) | Verwendung von Cystein oder N-Acetylcystein | |
DE602005002495T2 (de) | Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat | |
EP0349797B1 (de) | Stabilisierte, N-acetylcysteinhaltige Arzneimittelzubereitung | |
DD154802A5 (de) | Verfahren zur herstellung eines injizierbaren pharmazeutischen praeparates von prolongierter wirkung | |
DE1053736B (de) | Verfahren zur Erhoehung der Loeslichkeit therapeutisch wirksamer Stoffe in Wasser | |
DE3730957C2 (de) | Lösliches Thiamphenicol-Präparat | |
DE3689254T2 (de) | Arzneimittel auf Dextrorphanbasis zur intranasalen Applikation. | |
DE4309415C2 (de) | Pharmazeutisches Präparat | |
DE69118685T2 (de) | Zusammensetzungen für euthanasie | |
DE2221281C3 (de) | Pharmazeutische Zubereitungen mit entzündungshemmender und analgetischer Wirkung | |
DE2102889C3 (de) | Verwendung von SuIf adimidin und Pyrimethamin | |
DE2445400C3 (de) | Injizierbare einphasige Zubereitung und Verfahren zu ihrer Herstellung | |
DE2445401C3 (de) | Injizierbare, einphasige Zubereitung und Verfahren zu ihrer Herstellung | |
DE69003126T2 (de) | Chemische Zusammensetzungen. | |
DE3030314A1 (de) | Arzneimittel auf sulfonamidbasis | |
DE2518509B2 (de) | Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin | |
DE3530821C2 (de) | Luprostiolhaltige Lösung | |
DE1668563C3 (de) | Cer(lll)-L(+)-lactat, Verfahren zu seiner Herstellung und diese enthaltende pharmazeutische Präparate | |
DE1617433C (de) | Verfahren zur Herstellung von 5,5 Diphenyl hydantoin Natrium Losungen fur Injektionszwecke | |
DE69629919T2 (de) | Injizierbare Zusammensetzungen enthaltend Nimesulide | |
DD276032A5 (de) | Verfahren zur herstellung von arzneimittelpraeparaten zur behandlung von venenerweiterungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENJ | Ceased due to non-payment of renewal fee |